P01.122 Safety, immunogenicity and optimization of the IMA950 multipeptide vaccine combined with Poly-ICLC in newly diagnosed HLA-A2 malignant glioma patients

BACKGROUND: The clinical development of immunotherapy is still limited for patients with malignant glioma. We report the results of a phase I/II study of the IMA950 multipeptide vaccine adjuvanted with the TLR3 agonist poly-ICLC in association with radiochemotherapy in newly diagnosed HLA-A2+ malign...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Migliorini, D, Dutoit, V, Allard, M, Mohan, S, Lobrinus, A, Merkler, D, Vargas, M, Walker, P R, Patrikidou, A, Dietrich, P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Poster Presentations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144642/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.164
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars